Skip to content
Home/Companies/Biotech/EyeBio
EY

EyeBio

Biotech·US·Exited 2024·Held 2yr

EyeBio is a healthcare company, headquartered in France.

Entry
2022
Hold
2yr
Exit
2024
Est. EV
–

Who owns EyeBio?

EyeBio was owned by Jeito Capital through Jeito I (2021 vintage) from 2022 to 2024, exited via Trade Sale. Across its history, EyeBio has been through 2 private equity ownership periods, detailed in the timeline below.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Jeito Capital
Most recent investor
Jeito Capital
Jeito I · 2021 · VC
2 ownership periods · full history below

Key facts

HQFrance
SectorHealthcare
Key takeaways
  • ·Fully exited in 2024.
  • ·Average hold across 2 realized cycles: 3 years.

Ownership history

2 ownership periods · co-invest detected

Exited
Last exited in 2024 to .
Co-invest · 2 holders · 2021 · 2024
SV Health Managers
SV Health ManagersExited 2024
2021 · 2024 · SV7 Impact Medicine Fund · 2019 · Life Sciences VC
Trade Sale · to
MOIC
–
Jeito Capital
Jeito CapitalExited 2024
2022 · 2024 · Jeito I · 2021 · VC
Trade Sale · to
MOIC
–

More from Jeito I

Other portfolio companies in the same fund.

Corteria Pharmaceuticals
Active
BiotechFrance· 2023
Noema Pharma
Active
BiotechSwitzerland· 2023
Advesya
Active
BiotechSpain· 2022
CatalYm
Active
BiotechGermany· 2022
CDR-Life
Active
BiotechSwitzerland· 2022
NMD Pharma
Active
BiotechDenmark· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings